Market capitalization | AUD136.72b |
Enterprise Value | AUD155.53b |
P/E (TTM) P/E ratio | 33.76 |
EV/FCF (TTM) EV/FCF | 53.45 |
EV/Sales (TTM) EV/Sales | 6.94 |
P/S ratio (TTM) P/S ratio | 6.10 |
P/B ratio (TTM) P/B ratio | 5.25 |
Dividend yield | 1.41% |
Last dividend (FY24) | AUD3.97 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a CSL forecast:
15 Analysts have issued a CSL forecast:
Jun '24 |
+/-
%
|
||
Revenue | 22,426 22,426 |
14%
14%
|
|
Gross Profit | 10,920 10,920 |
15%
15%
|
|
EBITDA | 7,090 7,090 |
27%
27%
|
EBIT (Operating Income) EBIT | 5,659 5,659 |
30%
30%
|
Net Profit | 4,039 4,039 |
21%
21%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Paul McKenzie |
Employees | 32,000 |
Founded | 1961 |
Website | www.csl.com.au |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.